Free Trial
NASDAQ:ARDX

Ardelyx Q3 2025 Earnings Report

Ardelyx logo
$5.04 -0.02 (-0.40%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$5.03 -0.01 (-0.30%)
As of 10/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx EPS Results

Actual EPS
N/A
Consensus EPS
-$0.07
Beat/Miss
N/A
One Year Ago EPS
N/A

Ardelyx Revenue Results

Actual Revenue
N/A
Expected Revenue
$100.44 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ardelyx Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Thursday, October 30, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Ardelyx Earnings Headlines

Ardelyx (ARDX) Projected to Post Earnings on Thursday
Nvidia CEO’s Regret: ‘I Wish I Gave [Elon] More’…
Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Since then, we've seen a massive rollout of AI legislation, and the some of the stocks I recommended back then have doubled the market's return. Now I'm releasing a new "BUY LIST" to take advantage of Elon’s next launch, and giving away one name and ticker for free on this page here.tc pixel
Wedbush Weighs in on Ardelyx's FY2025 Earnings (NASDAQ:ARDX)
What is Wedbush's Estimate for Ardelyx FY2026 Earnings?
See More Ardelyx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ardelyx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ardelyx and other key companies, straight to your email.

About Ardelyx

Ardelyx (NASDAQ:ARDX) (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders. The company is advancing RDX8940, a non‐systemic, gut‐restricted TGR5 agonist intended for the treatment of nonalcoholic steatohepatitis (NASH) and other liver diseases. Additional programs focus on novel mechanisms to manage uremic toxins and intestinal sodium balance, reinforcing Ardelyx’s emphasis on gut‐targeted therapies that may improve patient outcomes without the safety risks of systemic drug exposure.

Founded in 2010 and headquartered in San Mateo, California, Ardelyx operates research and development facilities in the Bay Area, with a commercial infrastructure supporting product launch and patient access in the United States. The company has forged strategic collaborations—most notably with Mitsubishi Tanabe Pharma in Japan for the development and commercialization of tenapanor. Ardelyx’s leadership team, led by President and Chief Executive Officer Michael A. Raab, combines experience in drug discovery, regulatory affairs and commercial operations to drive its mission of bringing new treatment options to patients with high unmet medical needs.

View Ardelyx Profile

More Earnings Resources from MarketBeat